US-based in vitro fertilization (IVF) services provider Boston IVF has entered into strategic partnership with IviGen and its parent company, iGenomix, to provide comprehensive genetic testing services to its patients.

The partnership combines Boston IVF’s premier reproductive health services with IviGen’s advanced, genetics-based reproductive health products, such as preimplantation genetic screening (PGS), a test performed along with IVF to screen embryos for chromosomal abnormalities.

Boston IVF medical director and president Dr Michael Alper said: "We’re very pleased to be partnering with IviGen, a leader in the field of genetic testing, to provide the most advanced and productive testing services to our couples undergoing reproductive health counselling and treatments.

"This partnership will allow Boston IVF to offer the most advanced genetic screening technologies for IVF patients and their embryos, and at a price point that makes these technologies more readily available."

"This partnership will allow Boston IVF to offer the most advanced genetic screening technologies for IVF patients."

Boston IVF patients will have access to a preimplantation genetic diagnosis test that is performed with IVF treatment to identify single gene disorders among embryos produced by couples who are at risk of bearing a child with a particular genetic disease.

Additional genetic testing services to be made available include products of conception (POC) testing, endometrial receptivity array (ERA), as well as sperm aneupoloidy test (SAT).

POC tests tissue from a pregnancy loss for chromosome abnormalities in order to help determine the cause of the miscarriage, while ERA validates the expression of a group of genes related to endometrial receptivity to identify the optimal timing for embryo transfer and implantation.

SAT is a genetic test that determines whether there is an increased incidence of significant chromosome abnormalities in sperm.

IviGen and iGenomix CEO David Jimenez said: "This partnership also allows us to collaborate in the research and development of new tools to prevent infertility and improve treatment outcomes."